CMS clarifies Sunshine excludability

With reporting requirements kicking in this month under the Physician Payments Sunshine Act, CMS clarified how meals and expenses are to be treated under the so-called CME exemption.

CME speaker travel and lodging costs, CME attendee meals provided to a large group in a communal/buffet style, and most educational materials are “Sunshine exempt,” it said.

The guidance should let physicians take part in CME activities, on both sides of the podium, without concern for being named in the Act's database as recipients of industry dollars, said the CME Coalition, which had requested the clarification.

The coalition said it anticipates more guidance outlining possible additions to the list of accrediting bodies that are counted toward meeting the Sunshine-exemption criteria, and further clarification around meals.

The final rule outlines three conditions to exclude payments to faculty or speakers: payments must relate to an accredited event; not come directly from a manufacturer; and manufacturers cannot select speakers. Pharma, device makers and GPOs needed to start collecting data August 1 for anything “of value” ($10 per occasion, $100 per annum cumulative).

In a July presentation about the Act's implementation, Andrew Rosenberg, senior advisor to the CME Coalition, said commercial supporters should have enough comfort in the CME exemption to move forward without fear of penalty.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.